Report cover image

Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 195 Pages
SKU # IRE18436663

Description

Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Global Forecast 2024-2030


The Cancer Immunotherapy Market size was estimated at USD 73.38 billion in 2023 and expected to reach USD 77.39 billion in 2024, at a CAGR 5.54% to reach USD 107.11 billion by 2030.

Global Cancer Immunotherapy Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Immunotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Immunotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GSK PLC, Janssen Global Services, LLC, Merck & Co., Inc., Novartis International AG, OSE Immunotherapeutics SA, and Pfizer, Inc..

Market Segmentation & Coverage



This research report categorizes the Cancer Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Cell Therapies
Chimeric Antigen Receptor T Cell Therapy
Dendritic Cells
Checkpoint Inhibitors
Cytotoxic T-Lymphocyte-Associated Protein-4
Programmed Death 1 & Programmed Death Ligand 1
Immunomodulators
Granulocyte-Macrophage Colony-Stimulating Factor
Interferons
Interleukins
Oncolytic Virus
Monoclonal Antibodies
Bispecific Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Naked Monoclonal Antibodies
Vaccines
Prophylactic Vaccines
Therapeutic Vaccines
Function
Breast Cancer
Colorectal Cancer
Head & Neck Cancer
Lung Cancer
Melanoma
Multiple Myeloma
Prostate Cancer
End-User
Cancer Research Institutes
Clinics
Hospitals
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Immunotherapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Immunotherapy Market?
3. What are the technology trends and regulatory frameworks in the Cancer Immunotherapy Market?
4. What is the market share of the leading vendors in the Cancer Immunotherapy Market?
5. Which modes and strategic moves are suitable for entering the Cancer Immunotherapy Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

195 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Immunotherapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer patients worldwide
5.1.1.2. Increasing adoption of advanced cancer therapeutics
5.1.1.3. Surging investments in research and development activities of cancer treatment
5.1.2. Restraints
5.1.2.1. Capital intensive treatment and procedures
5.1.3. Opportunities
5.1.3.1. Extensive development of bioinformatics tools in drug development process
5.1.3.2. Growing number of clinical trials for cancer immunotherapy
5.1.4. Challenges
5.1.4.1. Complications in cancer limiting the immune response
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Immunotherapy Market, by Product
6.1. Introduction
6.2. Cell Therapies
6.3.1. Chimeric Antigen Receptor T Cell Therapy
6.3.2. Dendritic Cells
6.3. Checkpoint Inhibitors
6.4.1. Cytotoxic T-Lymphocyte-Associated Protein-4
6.4.2. Programmed Death 1 & Programmed Death Ligand 1
6.4. Immunomodulators
6.5.1. Granulocyte-Macrophage Colony-Stimulating Factor
6.5.2. Interferons
6.5.3. Interleukins
6.5.4. Oncolytic Virus
6.5. Monoclonal Antibodies
6.6.1. Bispecific Monoclonal Antibodies
6.6.2. Conjugated Monoclonal Antibodies
6.6.3. Naked Monoclonal Antibodies
6.6. Vaccines
6.7.1. Prophylactic Vaccines
6.7.2. Therapeutic Vaccines
7. Cancer Immunotherapy Market, by Function
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Head & Neck Cancer
7.5. Lung Cancer
7.6. Melanoma
7.7. Multiple Myeloma
7.8. Prostate Cancer
8. Cancer Immunotherapy Market, by End-User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals
9. Americas Cancer Immunotherapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Immunotherapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Immunotherapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amgen Inc.
13.1.2. AstraZeneca PLC
13.1.3. Avid Bioservices, Inc.
13.1.4. Bayer AG
13.1.5. Bristol-Myers Squibb
13.1.6. C.H. Boehringer Sohn AG & Ko. KG
13.1.7. ELI Lilly and Company
13.1.8. F. Hoffmann-La Roche Ltd
13.1.9. Gilead Sciences, Inc.
13.1.10. GSK PLC
13.1.11. Janssen Global Services, LLC
13.1.12. Merck & Co., Inc.
13.1.13. Novartis International AG
13.1.14. OSE Immunotherapeutics SA
13.1.15. Pfizer, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. CANCER IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. CANCER IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 7. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
FIGURE 10. CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. CANCER IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us